G1-S-specific cyclin-D1 inhib 
Welcome,         Profile    Billing    Logout  
 2 Companies  1 Product   1 Product   0 Diseases   12 Trials   244 News 


12345678910111213...2021»
  • ||||||||||  thapsigargin / University of Nottingham, Pirbright Institute
    Journal:  Induction of LARP1B under endoplasmic reticulum stress and its regulatory role in proliferation of esophageal squamous cell carcinoma. (Pubmed Central) -  Sep 29, 2024   
    ESCC cells exposed to ER stress stimulants (thapsigargin and tunicamycin) showed increased expression levels of LARP1B...Inhibiting CCND1 might partially counterbalance the proliferation-promoting impact of LARP1B overexpression on ESCC cells. These findings indicate that, upon ER stress, up-regulation of LARP1B, triggered by ERN1-XBP1 pathway, facilitates proliferation of ESCC cells through enhancing the mRNA stability of CCND1, and LARP1B may be used as a potential therapeutic target of ESCC.
  • ||||||||||  tamoxifen / Generic mfg.
    Journal:  Single cell profiling of female breast fibroadenoma reveals distinct epithelial cell compositions and therapeutic targets. (Pubmed Central) -  Jun 21, 2023   
    Individualized combinations of tamoxifen with ERBB2, BCL2 or CCND1 inhibitors could significantly suppress the viability of tamoxifen-resistant organoids. Thus, our study presents an overview of human FA at single-cell resolution that outlines the structural and functional differences between FA and normal breast epithelium and, in particular, provides a potential therapeutic strategy for breast FAs.
  • ||||||||||  Journal:  PVT1/miR-16/CCND1 axis regulates gastric cancer progression. (Pubmed Central) -  Feb 10, 2023   
    Moreover, either miR-16 inhibitor or CCND1 overexpression plasmid could reverse the promoting effects of PVT1 on the malignant biological behaviors of GC cells. In conclusion, PVT1 promoted CCND1 expression by negatively regulating miR-16 expression to enhance the viability, invasion and cell cycle progression of GC cells.
  • ||||||||||  Preclinical, Journal:  The Pt(S-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo. (Pubmed Central) -  Jul 30, 2022   
    PtCl2(S-pr-thiosal)2 treatment reduced expression of phosphorylated STAT3 and downstream-regulated molecules associated with cancer stemness and proliferation, NANOG, cyclin D3, and c-Myc, and expression of phosphorylated NFκB in vitro and in vivo. In conclusion, PtCl2(S-pr-thiosal)2 reduces STAT3 and NFκB phosphorylation resulting in inhibition of BCL1 cell proliferation and the triggering of apoptotic cell death.
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Icariside II attenuates vascular remodeling via Wnt7b/CCND1 axis. (Pubmed Central) -  Jul 10, 2022   
    ICS-II was found to be as effective as rapamycin, the positive control used in this study...In conclusion, our findings demonstrate that ICS-II possesses significant anti-proliferative qualities that counteracts aberrant vascular neointimal hyperplasia. This phenomenon most likely occurs due to suppression of the Wnt7b/CCND1 axis.
  • ||||||||||  Journal:  Mechanical force modulates macrophage proliferation via Piezo1-AKT-Cyclin D1 axis. (Pubmed Central) -  Jul 9, 2022   
    Conditional ablation of Ccnd1 inhibited periodontal macrophage proliferation and therefore delayed OTM. Overall, our findings highlight that proliferation driven by mechanical force is a key process by which macrophages infiltrate in periodontal tissue during OTM, where Piezo1-AKT-Ccnd1 axis plays a pivotal role.
  • ||||||||||  Journal:  Oral oncolytic treatment for chronic lymphocytic leukemia. (Pubmed Central) -  Apr 30, 2022   
    The use of oral-only oncolytics could be a viable option for reducing the risk of infection due to limiting exposure to healthcare settings. Current literature suggests oral oncolytics may be an option, but there are several considerations to evaluate including medication adherence, drug-drug interactions, adverse events, and financial toxicity.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal:  Proteomic Analysis of Hypoxia-Induced Senescence of Human Bone Marrow Mesenchymal Stem Cells. (Pubmed Central) -  Sep 7, 2021   
    Hypoxia of hBMSCs inhibited CCND1 expression but promoted ROS production and cell apoptosis through activating the PI3K-dependent signaling pathway. These findings provided a detailed characterization of the proteomic profiles related to hypoxia-induced senescence of hBMSCs and facilitated our understanding of the molecular mechanisms leading to stem cell senescence.
  • ||||||||||  Journal:  Upregulation of LINC01503 promotes cervical cancer progression by targeting the miR-615-3p/CCND1 axis. (Pubmed Central) -  Jun 22, 2021   
    Rescue experiments indicated that LINC01503 inhibition suppressed the invasion and proliferative ability of the tumor cells, a phenomenon that was reversed following miR-615-3p inhibition or CCND1 overexpression. Collectively, these data indicate that LINC01503 enhances the progression of cervical cancer cells via interaction with miR-615-3p/CCND1 axis.
  • ||||||||||  Review, Journal:  Molecular Pathogenesis of Mantle Cell Lymphoma. (Pubmed Central) -  Jun 2, 2021   
    A subset of patients with the SOX11-negative leukemic non-nodal MCL subtype follows an initial indolent clinical evolution and may not require treatment at diagnosis, although eventually may progress to an aggressive disease. We discuss the genetic and molecular alterations with impact on the cancer hallmarks that characterize the lymphomagenesis of the 2 MCL subtypes.
  • ||||||||||  Journal:  Bioinformatic analysis reveals MIR502 as a potential tumour suppressor in ovarian cancer. (Pubmed Central) -  May 29, 2021   
    Our results suggest that molecular profiling characterized by the gene expression of CTCs influences clinical factors in patients with HNSCC. MIR502, which is regulated by NRF1, acts as a tumour suppressor gene to accelerate apoptosis and suppress proliferation by targeting the Hippo signalling pathway in ovarian cancer.
  • ||||||||||  Journal:  Modulation of Klotho expression in injured muscle perturbs Wnt signaling and influences the rate of muscle growth. (Pubmed Central) -  May 27, 2021   
    Muscle inflammation was only slightly modulated by increased klotho expression, initially reducing the expression of M2-biased macrophage markers Cd163 and Cd206 at 3-days post-injury and later increasing the expression of pan-macrophage marker F480 and Cd68 at 21-days post-injury. Collectively, our study shows that Klotho modulates myogenesis and that increased expression accelerates muscle growth after injury.
  • ||||||||||  Biomarker, Journal, Liquid biopsy:  MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy. (Pubmed Central) -  May 26, 2021   
    In addition, we demonstrated the most significant pathways of the targets associated with cervical cancer progression (FDR-corrected p < 0.001). This study demonstrated that miRNA biomarkers may distinguish healthy cervix and CIN 3 and regulate important molecular pathways of carcinogenesis.
  • ||||||||||  Clinical, Journal:  Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. (Pubmed Central) -  May 25, 2021   
    P=N/A
    G1/S phase cell-cycle alterations occurred in 20.6% (507 of 2457) of patients; 99% of those patients (n = 501) harbored ≥1 characterized co-alteration (median, 4; range, 0-24). In 40 patients with G1/S phase cell-cycle alterations given CDK4/6 inhibitors as part of their regimen, significantly longer median progression-free survival (PFS) was observed when CDK4/6 inhibitor-based therapies matched a larger proportion of tumor alterations, often because CDK4/6 inhibitors were administered together with other drugs that were matched to genomic co-alterations, hence achieving a high matching score (high vs. low [≥50% vs. <50%] matching score, PFS, 6.2 vs. 2.0 months, P < 0.001 [n = 40] [multivariate]) and higher rate of stable disease ≥6 months or an objective response (57% vs. 21%, P = 0.048).CONCLUSIONIn summary, in cell-cycle-altered cancers, matched CDK4/6 inhibitors, as part of an individualized regimen targeting a majority of genomic alterations, was independently associated with longer PFS.TRIAL REGISTRATIONClinicalTrials.gov NCT02478931.FUNDINGJoan and Irwin Jacobs Fund, National Cancer Institute (P30 CA023100, R01 CA226803), and the FDA (R01 FD006334).
  • ||||||||||  Journal:  Circ_0000745 strengthens the expression of CCND1 by functioning as miR-488 sponge and interacting with HuR binding protein to facilitate the development of oral squamous cell carcinoma. (Pubmed Central) -  May 23, 2021   
    In 40 patients with G1/S phase cell-cycle alterations given CDK4/6 inhibitors as part of their regimen, significantly longer median progression-free survival (PFS) was observed when CDK4/6 inhibitor-based therapies matched a larger proportion of tumor alterations, often because CDK4/6 inhibitors were administered together with other drugs that were matched to genomic co-alterations, hence achieving a high matching score (high vs. low [≥50% vs. <50%] matching score, PFS, 6.2 vs. 2.0 months, P < 0.001 [n = 40] [multivariate]) and higher rate of stable disease ≥6 months or an objective response (57% vs. 21%, P = 0.048).CONCLUSIONIn summary, in cell-cycle-altered cancers, matched CDK4/6 inhibitors, as part of an individualized regimen targeting a majority of genomic alterations, was independently associated with longer PFS.TRIAL REGISTRATIONClinicalTrials.gov NCT02478931.FUNDINGJoan and Irwin Jacobs Fund, National Cancer Institute (P30 CA023100, R01 CA226803), and the FDA (R01 FD006334). Circ_0000745 regulated the expression of CCND1 partly by acting as miR-488 sponge and interacting with HuR protein, thus promoting the progression of OSCC.